Stock Events

Stock Events

ELI LILLY AND COMPANY 

zł5,712.00
12764
+zł212.00+3.85%Tuesday 14:59

Statistics

Day High
5,712
Day Low
5,712
52W High
5,712
52W Low
3,151.5
Volume
3
Avg. Volume
0
Mkt Cap
5.09T
P/E Ratio
-
Dividend Yield
0.48%
Dividend
27.26

Upcoming

Dividends

0.48%Dividend Yield
Sep 2026
zł6.44
Jun 2026
zł6.37
Mar 2026
zł6.35
Dec 2025
zł5.41
Sep 2025
zł5.46
10Y Growth
12%
5Y Growth
15.84%
3Y Growth
9.23%
1Y Growth
11.28%

Earnings

Feb 10Expected
Q4 2025
Q1 2026
Q2 2026
Q3 2026
Next
22.39
29.63
36.87
44.11
Expected EPS
44.11142588852999
Actual EPS
N/A

Financials

31.52%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
238.44BRevenue
75.17BNet Income

Analyst Ratings

$4,172.96Average Price Target
The highest estimate is ⁦4,765.37⁩.
From 17 ratings within the last 6 months. This is not an investment recommendation.
Buy
94%
Hold
0%
Sell
6%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LILY.WA. It's not an investment recommendation.
NVIDIA
4888
NVDA
Microsoft
4304
MSFT
Amazon
3231
AMZN
Apple
3159
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap173.95B
Pfizer competes directly with Eli Lilly in various therapeutic areas, including oncology, immunology, and cardiovascular diseases.
Merck
MRK
Mkt Cap368.89B
Merck is a key competitor in the pharmaceutical industry, particularly in the fields of oncology and diabetes, where both companies have significant investments.
Johnson & Johnson
JNJ
Mkt Cap657.68B
Johnson & Johnson competes with Eli Lilly through its pharmaceutical segment, particularly in immunology and oncology.
Novartis
NVS
Mkt Cap303.67B
Novartis competes in similar therapeutic areas as Eli Lilly, including neuroscience and oncology, with a strong focus on research and development.
Abbvie
ABBV
Mkt Cap521.11B
AbbVie competes with Eli Lilly in the immunology market, particularly in treatments for autoimmune diseases.
Bristol-Myers Squibb
BMY
Mkt Cap127.71B
Bristol Myers Squibb is a competitor in the oncology and cardiovascular markets, areas where Eli Lilly also operates.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca competes with Eli Lilly in several areas, including oncology, cardiovascular, and respiratory diseases.
GSK
GSK
Mkt Cap99.19B
GlaxoSmithKline competes with Eli Lilly in areas such as immunology and respiratory diseases.
Sanofi
SNY
Mkt Cap106.24B
Sanofi competes with Eli Lilly in diabetes care and vaccines, among other areas.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG competes with Eli Lilly in oncology and neuroscience, with a strong emphasis on biopharmaceuticals.

About

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Show More
CEO
David A. Ricks
Employees
50000
Country
United States
ISIN
US5324571083
WKN
000858560

Listings

BK
TH
LLY80.BK
MU
DE
LLY0.MU
STU
DE
LLY.STU
MI
IT
1LLY.MI

0 Comments

Share your thoughts

FAQs

What is ELI LILLY AND COMPANY stock price today?▼
The current price of LILY.WA is zł5,712.00 PLN — it has increased by +3.85% in the past 24 hours. Watch ELI LILLY AND COMPANY stock price performance more closely on the chart.
What is ELI LILLY AND COMPANY stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Warsaw Stock Exchange exchange ELI LILLY AND COMPANY stocks are traded under the ticker LILY.WA.
What is ELI LILLY AND COMPANY market cap?▼
Today ELI LILLY AND COMPANY has the market capitalization of 5.09T
When is the next ELI LILLY AND COMPANY earnings date?▼
ELI LILLY AND COMPANY is going to release the next earnings report on February 10, 2027.
What were ELI LILLY AND COMPANY earnings last quarter?▼
LILY.WA earnings for the last quarter are 29.33 PLN per share, whereas the estimation was 22.39 PLN resulting in a +30.99% surprise. The estimated earnings for the next quarter are N/A PLN per share.
What is ELI LILLY AND COMPANY revenue for the last year?▼
ELI LILLY AND COMPANY revenue for the last year amounts to 238.44B PLN.
What is ELI LILLY AND COMPANY net income for the last year?▼
LILY.WA net income for the last year is 75.17B PLN.
Does ELI LILLY AND COMPANY pay dividends?▼
Yes, LILY.WA dividends are paid quarterly. The last dividend per share was 6.44 . As of today, Dividend Yield (FWD)% is 0.48%.
How many employees does ELI LILLY AND COMPANY have?▼
As of November 4, 2026, the company has 50,000 employees.
In which sector is ELI LILLY AND COMPANY located?▼
ELI LILLY AND COMPANY operates in the Health & Wellness sector.
When did ELI LILLY AND COMPANY complete a stock split?▼
ELI LILLY AND COMPANY has not had any recent stock splits.
Where is ELI LILLY AND COMPANY headquartered?▼
ELI LILLY AND COMPANY is headquartered in INDIANAPOLIS, United States.